

ANNUAL REPORT

2018 Annual Report of the European Liver Transplant Registry (ELTR) – 50-year evolution of liver transplantation

René Adam¹, Vincent Karam¹, Valérie Cailliez¹, John G. O Grady², Darius Mirza³, Daniel Cherqui¹, Jurgen Klempnauer⁴, Mauro Salizzoni⁵, Johann Pratschke⁶, Neville Jamieson⁷, Ernest Hidalgo⁸, Andreas Paul⁹, Rafael Lopez Andujar¹⁰, Jan Lerut¹¹, Lutz Fisher¹², Karim Boudjema¹³, Constantino Fondevila¹⁴, Olivier Soubrane¹⁵, Philippe Bachellier¹⁶, Antonio D. Pinna¹⁷, Gabriela Berlakovich¹⁸, William Bennet¹⁹, Massimo Pinzani²⁰, Peter Schemmer²¹, Krzysztof Zieniewicz²², Carlos Jimenez Romero²³, Paolo De Simone²⁴, Bo-Goran Ericzon²⁵, Stefan Schneeberger²⁶, Stephen J. Wigmore²⁷, Joan Fabregat Prous²⁸, Michele Colledan²⁹, Robert J. Porte³⁰, Sezai Yilmaz³¹, Daniel Azoulay³², Jacques Pirenne³³, Pal-Dag Line³⁴, Pavel Trunecka³⁵, Francis Navarro³⁶, Andres Valdivieso Lopez³⁷, Luciano De Carlis³⁸, Sebastian Rufian Pena³⁹, Eberhard Kochs⁴⁰ & Christophe Duvoux³² all the other 126 contributing centers (www.eltr.org) and the European Liver and Intestine Transplant Association (ELITA)

1 Paul Brousse Hospital, Univ Paris-Sud, Inserm U935, Villejuif, France

2 King's College Hospital, London, UK

3 The Queen Elizabeth Hospital, Birmingham, UK

4 Medizinische Hochschule Hannover, Hannover, Germany

5 Centro de Trapianti di Fegato, Torino, Italy

6 Charité- Campus – Virchow Klinikum, Berlin, Germany

7 Addenbrooke's Hospital, Cambridge, UK

8 St James' & Seacroft University Hospital, Leeds, UK

9 C. U. K. GHs Essen, Essen, Germany

10 Hospital Universitario LA FE, Valencia, Spain

11 Cliniques Universitaires Saint Luc, Brussels, Belgium

12 Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany

13 C.H.U. Rennes, Hopital De Pontchaillou, Rennes, France

14 Hospital Clinic I Provincial de Barcelona, Barcelona, Spain

15 Hopital Beaujon, Clichy, France

16 C.H.R.U. De Strasbourg, Strasbourg, France

17 University of Bologna, Bologna, Italy

SUMMARY

The purpose of this registry study was to provide an overview of trends and results of liver transplantation (LT) in Europe from 1968 to 2016. These data on LT were collected prospectively from 169 centers from 32 countries, in the European Liver Transplant Registry (ELTR) beginning in 1968. This overview provides epidemiological data, as well as information on evolution of techniques, and outcomes in LT in Europe over more than five decades; something that cannot be obtained from only a single center experience.

Transplant International 2018; 31: 1293–1317

Key words

liver transplantation, outcome, registry

Received: 18 May 2018; Revision requested: 19 June 2018; Accepted: 22 September 2018

Correspondence

René Adam MD, PhD, Centre Hépatobiliaire, Hôpital Paul Brousse, 12-14, Av Paul-Vaillant-Couturier, B.P. 200, Villejuif Cedex F-94804, France.

Tel: 33 1 45 59 32 88

fax: 33 1 45 59 38 57

e-mail: rene.adam@aphp.fr

The order of the co-authors from 2 to 40 was determined according to the decreasing number of liver transplants recorded in the ELTR.

The list with all the centers is available at the following link: <http://www.eltr.org/spip.php?page=centers-tous>

- 18 Department of Surgery, Medical University of Vienna, Vienna, Austria
 - 19 Sahlgrenska University Hospital, Gothenborg, Sweden
 - 20 Royal Free Hospital, London, UK
 - 21 Universitätsklinikum Heidelberg, Heidelberg, Germany
 - 22 Medical University of Warsaw Banacha, Warsaw, Poland
 - 23 Hospital 12 De Octubre, Madrid, Spain
 - 24 Ospedale Cisanello, Pisa, Italy
 - 25 Huddinge Hospital, Huddinge, Sweden
 - 26 University Hospital, Innsbruck, Austria
 - 27 University of Edinburgh Royal Infirmary, Edinburgh, UK
 - 28 Hospital Universitari De Bellvitge, Barcelona, Spain
 - 29 Papa Giovanni 23 Hospital, Bergamo, Italy
 - 30 University Medical Center Groningen, Groningen, The Netherlands
 - 31 Inonu Universitesi, Malatya, Turkey
 - 32 Hôpital Henri Mondor, Créteil, France
 - 33 Universitaire Ziekenhuizen Leuven, Leuven, Belgium
 - 34 Rikshospitalet, Oslo, Norway
 - 35 Transplant Center, Institute for Clinical and Experimental Medicine (IKEM), Prague, Czech Republic
 - 36 Hopital Saint Eloi, Montpellier, France
 - 37 Hospital De Cruces, Baracaldo Vizcaya, Spain
 - 38 Ospedale Niguarda Ca Granda, Milano, Italy
 - 39 Hospital Universitario Reina Sofia, Cordoba, Spain
 - 40 Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar, Munich, Germany
-

Introduction

Background of the European Liver Transplant Registry

Created in 1986, the ELTR has collected the data of liver transplantation (LT) from 175 centers all over Europe since 1968. The registered data represents more than 95% of the overall European data compared with the published official figures [1].

Questionnaire

The ELTR questionnaire includes data on indications for LT, donors and recipients characteristics, technical aspects of LT (with reduced, split, domino, live and nonheart beating donors), initial and current regimen of immunosuppression, patient outcomes, and cause of death or graft failure. The ELTR has developed an online application (Electronic Data Capture – EDC) for collecting data. A Web-based module was developed to allow for real-time data capture. Software, questionnaires, validation routines, and statistics are located on a central server, which can be accessed by the participating centers with a standard internet browser [2].

To avoid an overlap in case of multiple diagnoses, the ELTR has two variables to report the diagnosis

(Disease1 & Disease2) and an open field for specification in case a diagnosis is not available in the official pull-down menu, or in case there are more than two combined diagnoses. A standard procedure was stated accordingly for the data entry and their analysis in each condition.

Quality control of the data

The data-entry process is dynamically controlled. The data are subjected to routine checks for completeness, consistency, and range. Comprehensive logical intra- and inter-updates are performed. In addition, a control of the good adequacy between ELTR questionnaire and patient charts is performed by randomly conducted audit visits to the centers. The ELTR audit visits have been continuously conducted since 1998 with, initially 10 randomly selected centers per year up to the year 1999, and five centers per year since 2000. Two auditors perform the visit with the condition that both are not from the visited country. Ten percent of center's files, with a minimum of 20 and a maximum of 50, are analyzed to check data for completeness and consistency. The audit visits serve also to train staff members, and to introduce amendments in the procedure. It is also the opportunity to meet

with the staff of centers, something that is valuable for creating a team spirit. The ELTR is considered as the pioneer of external audit visits of a scientific registry. The audit report is sent confidentially to the head of the center with all the discrepancies noted, and the recommendations necessary to improve the data entry included. The results of all center audits are presented during the ELTR biennial workshops, where all the contributing centers are invited. A recent analysis of the ELTR audit data (38 centers from 16 countries, 57 575 variables from 1458 patient files, from 2010 to 2016) showed that the overall rates of completeness and consistency were 94.5% and 97.3% respectively. Audit visits are an indicator of the quality of data, and represent one of the pillars of the ELTR. These results have indicated that ELTR data are reliable, and the scientific results of ELTR can be considered credible and representative of LT in Europe [3–6].

Partnership with organ sharing organizations (OSOs)

The ELTR has established agreements with the main national and international OSOs: United Kingdom Transplant Service Support Authority – UK NHS Blood and Transplant, Spanish Organizacion Nacional de Trasplantes – ONT, Scandinavian Scandiatransplant – SKT, Dutch Transplant Foundation – NTS, Eurotransplant Foundation – ET, French Agence de la Biomédecine – ABM to exchange data collected from European Centers and to cross check common data between OSO and ELTR.

Source of the data

There are two sources of ELTR data; 72% of data (63% of centers) are shared with the OSOs and 28% of data (37% of centers) are directly entered into the ELTR EDC platform. Some variables were added to the




Figure 1 Number of LTs performed in each country, overall and living related liver transplantation (LRLT)(May 1968–December 2016).




Figure 2 Evolution of 147 161 LTs performed in Europe since May 1968.

questionnaire, and some definitions have changed since the registry was created in 1986. To adapt the ELTR to these evolutions, an experts committee was appointed to oversee the standardization of the questionnaire. The European Liver and Intestine Transplant Association (ELITA) board and the OSOs share this concern and are also attentive to all the evolutions.

Previous ELTR achievements

The ELTR regularly carries out thematic studies related to the different fields of LT. These studies minimize the potential biases, by assessing interactions between confounding factors and identification of independent predictors among all the ELTR variables that can have an impact on the outcome. A sample of these studies is cited in the references of the manuscript. With reports concerning LT for specific hepatic diseases [7–24], analysis of the impact of the type of preservation solution [25], and of the immunosuppressive regimen on the patient outcome [26], ELTR has helped develop risk models for mortality following liver-transplantation [27,28]. Owing to the large cohort of patients, the exhaustiveness, and quality of the data, and the long

follow-up provided by the ELTR, the results are really representative of LT in Europe.

The objective of this paper is to report these results and their evolution in adults as well as in pediatric recipients.

Patients and methods

The whole data since 1968 was considered initially to show the evolution of results of LT in Europe since its initial development. The rest of analysis was then undertaken considering two different periods: (i) January 1988 to December 2016 (147 161 LT – 127 851 patients) [January 1988 was chosen corresponding to the introduction and widespread use of cyclosporine-based immunosuppression, and standardization of the surgical procedure], (ii) the last 15-year period data from January 2002 to December 2016 (99 562 LT – 91 183 patients) to give a more recent evaluation of LT results in Europe.

Data were generally analyzed as a whole (except for some variables), without making a distinction between adult and pediatric population, the latter representing 10% of LT in Europe.

Table 1. Primary indication of LT in Europe and the corresponding graft and patient survival rate.

Indication of LT	From 1988 to 2016										Last 15 years									
	N	% of the disease	% of the Total	Survival rate	N	1 year, %	5 years, %	10 years, %	15 years, %	20 years, %	N	% of the disease	% of the Total	Survival rate	N	1 year, %	5 years, %	10 years, %	15 years, %	
																				N
Acute hepatic failure	9485	7	0.1	Graft Patient	9268	66	58	52	45	37	6240	7	0.1	Graft Patient	6080	70	62	55	46	
Fulminant or Subfulminant hepatitis	7485	6	0.1	Graft Patient	7291	66	59	53	46	38	4606	5	0.1	Graft Patient	4466	71	64	57	50	
Virus A	163	2	0.1	Graft Patient	160	61	57	52	43	32	111	2	0.1	Graft Patient	109	65	61	61	61	
Virus B	917	12	1	Graft Patient	909	69	62	57	50	40	578	13	1	Graft Patient	571	74	67	64	52	
Virus C	127	2	0.1	Graft Patient	125	65	53	39	32	25	80	2	0.1	Graft Patient	78	68	50	35	61	
Virus D	14	0.2	0.01	Graft Patient	14	76	67	46	46	46	4	0.1	0.004	Graft Patient	4	100	100	67	67	
Other known	797	11	1	Graft Patient	776	68	61	56	49	40	565	12	1	Graft Patient	547	71	64	57	100	
Other unknown	3647	49	3	Graft Patient	3585	65	58	53	46	39	1966	43	2	Graft Patient	1922	71	65	59	50	
Paracetamol	743	10	1	Graft Patient	671	69	59	50	45	32	531	12	1	Graft Patient	477	74	64	53	43	
Other drug related: specify	715	10	1	Graft Patient	668	74	65	58	54	43	472	10	1	Graft Patient	476	78	70	63	59	
Toxic (hondrug)	362	5	0.3	Graft Patient	359	63	58	51	44	29	299	6	0.3	Graft Patient	297	63	58	48	48	
Traumatic acute hepatic failure	430	0.3	0.3	Graft Patient	430	48	39	35	31	31	346	0.4	0.4	Graft Patient	346	52	41	36	54	
Postoperative	173	40	0.1	Graft Patient	173	30	20	17	17	43	138	40	0.2	Graft Patient	138	33	21	17	44	
Post-traumatic	257	60	0.2	Graft Patient	257	61	52	48	45	45	208	60	0.2	Graft Patient	208	65	55	49	30	
Subacute hepatic failure	1570	1	1	Graft Patient	256	65	57	54	54	54	1288	1	1	Graft Patient	208	69	60	54	54	
Virus A	10	1	0.01	Graft Patient	10	67	50	50	50	50	8	1	0.01	Graft Patient	8	71	48	48	66	
Virus B	130	8	0.1	Graft Patient	127	80	65	54	20	49	113	9	0.1	Graft Patient	111	80	68	63	66	
Virus C	184	12	0.1	Graft Patient	184	75	56	32	18	28	161	13	0.2	Graft Patient	161	75	55	33	66	
Virus D	6	0.4	0.005	Graft Patient	6	67	67	67	67	67	4	0.3	0.004	Graft Patient	4	75	75	75	34	
Other known	62	4	0.05	Graft Patient	61	76	66	66	66	66	54	4	0.1	Graft Patient	53	80	68	68	50	
Other unknown	278	18	0.2	Graft Patient	267	77	71	64	64	64	207	16	0.2	Graft Patient	198	80	71	67	58	
Paracetamol	5	0.3	0.004	Graft Patient	5	67	67	67	65	53	4	0.3	0.004	Graft Patient	4	100	100	76	64	
Other drug related: specify	60	4	0.05	Graft Patient	56	62	55	49	41	41	51	4	0.1	Graft Patient	47	66	57	53	53	
Toxic (non drug)	24	2	0.02	Graft Patient	23	78	68	54	27	27	17	1	0.02	Graft Patient	16	87	80	80	80	
Other acute hepatic failure: specify	811	52	1	Graft Patient	808	65	54	46	40	29	669	52	1	Graft Patient	666	67	53	46	25	

Table 1. Continued.

Indication of LT	From 1988 to 2016					Last 15 years														
	N patients	% of the disease	Total	Survival rate	N	1 year, %	5 years, %	10 years, %	15 years, %	20 years, %	N patients	% of the disease	Total	Survival rate	N	1 year, %	5 years, %	10 years, %	15 years, %	
Fulminant or subfulminant or subacute hepatitis	11 625	9									7638	8								
Viral	1551	13	1	Graft Patient	1535	70	60	53	45	36	1054	14	1	Graft Patient	1046	73	63	57	46	
Virus B	1047	9	1	Graft Patient	1529	75	66	58	52	43	691	9	1	Graft Patient	1043	78	68	61	55	
Drug-related	1523	13	1	Graft Patient	1032	76	69	63	57	47	1058	14	1	Graft Patient	682	75	67	64	51	
Paracetamol	748	6	1	Graft Patient	1420	73	66	57	52	43	535	7	1	Graft Patient	989	73	65	55	50	
Other drugs	775	7	1	Graft Patient	673	74	65	58	54	43	523	7	1	Graft Patient	988	77	70	62	60	
Toxic (nondrug)	386	3	0.3	Graft Patient	748	68	61	49	44	35	316	4	0.3	Graft Patient	480	78	70	63	59	
Unknown or others	5595	48	4	Graft Patient	382	64	59	51	44	29	3461	45	4	Graft Patient	508	72	65	56	56	
Cholestatic disease	13 241	10		Graft Patient	5497	66	59	53	47	39	8439	9		Graft Patient	312	69	65	56	56	
Secondary biliary cirrhosis	976	7	1	Graft Patient	5488	72	66	61	55	48	8242	84	74	Graft Patient	3382	77	70	64	55	
Primary biliary cholangitis	5865	44	5	Graft Patient	12 917	82	73	62	50	38	8221	90	81	Graft Patient	8242	84	74	63	52	
Primary sclerosing cholangitis	5786	44	5	Graft Patient	12 883	87	79	71	59	46	693	8	1	Graft Patient	8221	90	81	73	62	
Other cholestatic disease: specify	614	5	0.5	Graft Patient	955	72	62	54	47	39	4274	5		Graft Patient	679	73	62	54	49	
Congenital biliary disease	6397	5		Graft Patient	955	79	69	62	56	48	207	5	0.2	Graft Patient	679	80	69	63	58	
Caroli disease	258	4	0.2	Graft Patient	5698	83	76	66	54	41	3050	36	3	Graft Patient	2971	86	78	68	59	
Extrahepatic biliary atresia	5232	82	4	Graft Patient	5688	87	80	71	58	45	4248	50	5	Graft Patient	2966	90	83	74	64	
Congenital biliary fibrosis	194	3	0.2	Graft Patient	5682	83	71	58	45	31	4172	85	73	Graft Patient	4172	85	73	59	46	
Cholelithiasis	41	1	0.03	Graft Patient	5663	89	80	71	60	46	448	5	0.5	Graft Patient	4160	91	82	74	60	
Alagille syndrome	338	5	0.3	Graft Patient	582	80	74	68	58	50	448	5	0.5	Graft Patient	420	79	71	66	62	
Other congenital biliary disease: specify	334	5	0.3	Graft Patient	577	86	82	78	69	64	4274	5		Graft Patient	416	86	80	77	71	
Cirrhosis	64 166	50		Graft Patient	6248	82	77	73	68	63	4566	50		Graft Patient	4180	85	81	77	68	
Alcoholic cirrhosis	24 380	38	19	Graft Patient	6234	88	85	83	80	76	18 135	40	20	Graft Patient	4174	91	88	87	85	
Autoimmune Cirrhosis	2929	5	2	Graft Patient	257	81	74	66	57	52	207	5	0.2	Graft Patient	206	82	74	62	78	
Virus B related cirrhosis	5822	9	5	Graft Patient	257	89	84	80	70	66	3403	80	4	Graft Patient	206	90	86	78	78	

Table 1. Continued.

Indication of LT	From 1988 to 2016						Last 15 years												
	N patients	% of the disease	% of the Total	Survival rate	N	1 year, %	5 years, %	10 years, %	15 years, %	20 years, %	N patients	% of the disease	% of the Total	Survival rate	N	1 year, %	5 years, %	10 years, %	15 years, %
Virus C related cirrhosis	15 187	24	12	Graft	15 062	77	60	47	37	26	10 495	23	12	Graft	10 396	78	59	46	36
Virus BD related cirrhosis	1939	3	2	Patient	15 051	80	64	52	41	30	10 387	3	2	Patient	10 387	81	64	51	40
Virus BC related cirrhosis	829	1	1	Graft	1899	89	84	79	74	67	1431	3	2	Graft	1403	89	84	79	75
Virus BCD related cirrhosis	174	0.3	0.1	Patient	1895	92	88	84	81	73	559	1	1	Patient	1401	93	89	83	78
Virus related cirrhosis-Other viruses: specify	1994	3	2	Graft	819	78	64	54	42	31	134	0.3	0.1	Graft	552	80	66	54	34
Combined virus C and alcoholic cirrhosis	1996	3	2	Graft	170	88	78	62	47	33	1353	3	1	Graft	130	88	78	67	39
Combined virus B and alcoholic cirrhosis	489	1	0.4	Patient	170	88	78	62	47	33	1353	3	1	Patient	130	88	78	67	39
Posthepatic cirrhosis-Drug related	77	0.1	0.1	Graft	170	88	78	62	47	33	1353	3	1	Graft	130	88	78	67	39
Other cirrhosis: specify	2732	4	2	Patient	170	88	78	62	47	33	1353	3	1	Patient	130	88	78	67	39
Cryptogenic (unknown) cirrhosis	5618	9	4	Graft	5514	78	67	56	46	34	3808	8	4	Graft	3741	83	69	57	45
Primary liver tumors	21 135	17	17	Patient	5507	81	72	61	50	37	17 329	19	19	Patient	3737	83	73	61	47
Hepatocellular carcinoma and cirrhosis	18 349	87	14	Graft	20 976	81	60	47	36	28	17 329	19	19	Graft	17 206	83	64	49	37
Hepatocellular carcinoma and noncirrhotic liver carcinoma – Fibrolamellar	734	3	1	Patient	20 971	84	64	50	39	31	15 617	90	17	Patient	17 202	87	67	53	40
Biliary tract carcinoma (Klatskin)	51	0.2	0.04	Graft	18 225	82	62	48	36	28	15 617	90	17	Graft	15 510	84	65	49	38
Hepatic cholangiocellular carcinoma	395	2	0.3	Patient	18 220	86	66	51	39	31	425	2	0.5	Patient	15 506	87	68	53	40
Hepatoblastoma	216	1	0.2	Graft	726	72	49	34	24	18	26	0.2	0.03	Graft	423	81	61	44	24
Epithelioid hemangioendothelioma	17	0.1	0.01	Patient	726	77	52	37	27	20	26	0.2	0.03	Patient	423	87	66	48	24
Angiosarcoma	466	2	0.4	Graft	51	76	38	33	27	27	26	0.2	0.03	Graft	26	85	45	25	17
Other liver malignancies: specify	639	53	0.5	Patient	51	80	41	36	36	36	3	0.02	0.003	Patient	26	88	47	22	22
Secondary liver tumors	341	53	0.3	Graft	394	65	34	26	16	13	330	2	0.4	Graft	325	84	77	73	73
Carcinoid	341	53	0.3	Patient	394	72	41	35	24	21	216	1	0.2	Patient	325	88	83	79	79
				Graft	526	66	32	23	16	14	161	1	0.2	Graft	158	85	73	65	60
				Patient	526	69	33	25	19	15	3	0.02	0.003	Patient	158	91	79	71	65
				Graft	372	83	75	71	70	61	3	0.02	0.003	Graft	3	67	62	57	45
				Patient	372	87	80	77	75	66	216	1	0.2	Patient	3	67	62	57	45
				Graft	213	85	72	67	61	58	211	1	0.2	Graft	211	85	65	62	44
				Patient	213	90	77	71	67	60	395	0.4	0.4	Patient	211	85	65	62	44
				Graft	636	75	48	32	24	19	395	0.4	0.4	Graft	393	79	57	44	33
				Patient	636	80	52	34	26	21	185	47	0.2	Patient	393	85	61	46	36
				Graft	339	78	52	34	24	19	185	47	0.2	Graft	183	83	64	51	38
				Patient	339	82	55	36	27	22	183	47	0.2	Patient	183	87	67	54	41

Table 1. Continued.

Indication of LT	From 1988 to 2016										Last 15 years									
	N patients	% of the disease	% of the Total	Survival rate	N	1 year, %	5 years, %	10 years, %	15 years, %	20 years, %	N patients	% of the disease	% of the Total	Survival rate	N	1 year, %	5 years, %	10 years, %	15 years, %	
Other neuroendocrine	188	29	0.1	Graft	188	74	51	40	34		140	35	0.2	Graft	140	76	56	44	36	
				Patient	188	80	56	43	35					Patient	140	83	61	45	37	
Colorectal	73	11	0.1	Graft	72	73	24	3			53	13	0.1	Graft	53	81	24			
				Patient	72	80	26	3						Patient	53	85	29			
GI noncolorectal	18	3	0.01	Graft	18	60	35	20	10		8	2	0.01	Graft	8	45	23	23	23	
				Patient	18	60	35	20	10					Patient	8	45	23	23	23	
Nongastrointestinal	19	3	0.01	Graft	19	61	41	20			9	2	0.01	Graft	9	76	57			
				Patient	19	72	50	27						Patient	9	100	80			
Metabolic disease	7414		6	Graft	7188	82	73	64	55	48	5336		6	Graft	5166	83	74	63	52	
				Patient	7163	87	79	71	63	56				Patient	5147	88	80	71	60	
Wilson disease	1241	17	1	Graft	1200	83	78	71	64	56	904	17	1	Graft	879	85	79	72	65	
				Patient	1191	89	86	81	76	69				Patient	875	92	87	82	77	
Hemochromatosis	622	8	0.5	Graft	610	74	63	48	36	28	399	7	0.4	Graft	390	77	65	47	40	
				Patient	609	77	66	51	38	29				Patient	389	80	69	50	41	
Alpha-1 – Antitrypsin deficiency	717	10	1	Graft	678	83	75	66	58	44	478	9	1	Graft	457	84	76	68	54	
				Patient	678	87	81	72	65	56				Patient	457	88	81	73	61	
Glycogen storage disease	145	2	0.1	Graft	142	87	84	77	68	68	118	2	0.1	Graft	115	88	83	69	61	
				Patient	142	94	92	86	76	76				Patient	115	95	92	81	81	
Homozygous Hypercholesterolemia	36	0.5	0.03	Graft	36	86	81	65	65	65	29	1	0.03	Graft	29	85	80			
				Patient	36	86	81	65	65	65				Patient	29	85	80			
Tyrosinemia	122	2	0.1	Graft	119	85	75	73	71	65	65	1	0.1	Graft	62	87	84	84	84	
				Patient	118	91	86	84	84	84				Patient	62	90	87	87	87	
Familial amyloidotic polyneuropathy	1261	17	1	Graft	1241	82	73	62	50	38	866	16	1	Graft	847	83	73	62	50	
				Patient	1231	88	79	68	56	46				Patient	837	90	81	69	50	
Primary hyperoxaluria	332	4	0.3	Graft	326	79	72	62	53	50	264	5	0.3	Graft	258	78	73	61	33	
				Patient	326	84	77	68	58	58				Patient	258	84	79	67	25	
Protoporphyrin	19	0.3	0.01	Graft	19	77	77	70	61	51	8	0.1	0.01	Graft	8	69	69			
				Patient	19	77	77	70	61	51				Patient	8	69	69			
Other porphyria	17	0.2	0.01	Graft	17	81	65	65	65	65	13	0.2	0.01	Graft	13	83	83			
				Patient	17	87	65	65	65	65				Patient	13	91	82			
Nonalcoholic steatohepatitis (NASH)	749	10	1	Graft	706	83	72	51			748	14	1	Graft	705	83	72	52		
				Patient	705	86	75	54						Patient	704	86	75	55		
Crigler-Najjar	93	1	0.1	Graft	88	86	74	72	72	72	65	1	0.1	Graft	60	84	70	66		
				Patient	88	94	89	89	89	89				Patient	60	95	91	91		
Cystic fibrosis	277	4	0.2	Graft	272	83	68	63	57	46	233	4	0.3	Graft	228	86	73	68		
				Patient	271	85	74	64	57	45				Patient	227	88	76	70		
Byler disease	251	3	0.2	Graft	250	85	81	78	71	71	137	3	0.2	Graft	136	88	82	74	59	
				Patient	250	94	92	89	85	85				Patient	136	94	92	90	79	
Other metabolic disease	1532	21	1	Graft	1484	81	71	63	55	49	1009	19	1	Graft	979	83	72	63	54	
				Patient	1482	86	77	71	63	57				Patient	977	88	79	72	65	
Budd Chiari	1069		1	Graft	1052	73	65	57	49	39	715		1	Graft	704	77	67	58	49	
				Patient	1051	79	72	65	57	49			0	Patient	704	82	74	65	57	
Benign liver tumors or Polycystic disease	1824		1	Graft	1804	85	80	70	60	52	1516		2	Graft	1499	87	81	71	60	
				Patient	1804	88	84	75	65	56				Patient	1499	90	86	76	64	
Hepatic adenoid	38	2	0.03	Graft	38	65	47	40	40	40	30	2	0.03	Graft	30	70	44	44		
				Patient	38	71	55	55	55	55				Patient	30	73	52	52		
Adenomatosis	51	3	0.04	Graft	49	81	81	81	81	81	45	3	0.05	Graft	43	81	81	81		
				Patient	49	87	87	87	87	87				Patient	43	88	88	88		
Hemangioma	71	4	0.1	Graft	71	75	69	64	64	64	45	3	0.05	Graft	45	73	64	64	64	
				Patient	71	80	77	71	71	71				Patient	45	75	69	69	69	

Table 1. Continued.

Indication of LT	From 1988 to 2016										Last 15 years									
	N patients	% of the disease	% of the Total	Survival rate	N	1 year, %	5 years, %	10 years, %	15 years, %	20 years, %	N patients	% of the disease	% of the Total	Survival rate	N	1 year, %	5 years, %	10 years, %	15 years, %	
Focal nodular hyperplasia	12	1	0.01	Graft	12	75	64	21			10	1	0.01	Graft	10	80	80	27		
Polycystic disease	1493	82	1	Graft	1478	87	82	32	62	52	1293	85	1	Graft	1280	88	83	73	61	
Nodular regenerative hyperplasia	25	1	0.02	Patient	25	88	71	36	36	36	17	1	0.02	Patient	17	100	83	83	65	
Other benign tumors: specify	134	7	0.1	Graft	131	79	71	60	49	44	76	5	0.1	Graft	74	82	73	56	56	
Parasitic disease	101		0.1	Graft	101	77	69	58	40	20	71		0.1	Graft	71	81	70	70	62	
Schistosomia (Bilharzia)	2	2	0.002	Patient	2	50	50	50	50	27	1	1	0.001	Patient	1	84	73	73		
Alveolar echinococcosis	58	57	0.05	Graft	58	88	80	66	66	66	49	69	0.1	Graft	49	90	78	78		
Cystic hydatidosis	11	11	0.01	Patient	11	72	57	29	29	29	8	11	0.01	Patient	8	74	49	80		
Other parasitic disease: specify	30	30	0.02	Patient	30	68	64	52	33	33	13	18	0.01	Patient	13	60	60	60		
Other liver disease	2380		2	Graft	2325	73	64	56	50	42	1302		1	Graft	1264	75	67	59	43	
TPN-induced cholestasis	11	0.5	0.01	Patient	11	71	54	61	55	47	10	1	0.01	Patient	10	68	46	49		
Hepatopulmonary syndrome	19	1	0.01	Graft	18	78	78	78			19	1	0.02	Graft	18	78	78	78		
Other liver diseases: nonspecified	2350	99	2	Patient	2296	73	64	56	50	42	1273	98	1	Graft	1233	75	67	59	43	
Total	127 851		100		2289	77	69	61	55	47	91 183		100		1232	80	72	64	49	

Kaplan–Meier analysis was used to estimate graft and patient survival stratified by conditions group; statistical analyzes were performed using the log-rank test ($P < 0.05$ as significant) with SAS[®] Version 9.1.3 Enterprise Guide version 5.1 (Copyright© 2012 by SAS Institute Inc., Cary, NC, USA). The dynamics of data control was continued during the statistical analyzes. Calculation of survival rates was determined by the actuarial method.

Results

From May 1968 to December 2016, the ELTR has collected data concerning 146 782 LTs in 132 466 patients, from 169 Centers, and 32 countries (Fig. 1). These data give a comprehensive overview of the status and evolution of LT in Europe. Both the number of transplant centers and the annual number of LT's performed in Europe have gradually increased since the ELTR was created (Fig. 2). However, after an exponential increase from the eighties, a plateau seems to have been reached in recent years with about 7300 LTs performed all over Europe annually.

Main indications of LT in Europe

The main indications for LT in Europe with the corresponding graft and patient survival rates at 1, 5, 10, and 15 years in the whole ELTR population and in the last 15 years cohort are listed in Table 1. Twenty-year survival is provided for the whole ELTR population. Cirrhosis was the most frequent indication (50%), mainly related to either viral infection (22% with 12% of hepatitis C virus (HCV) infection and 5% of hepatitis B virus (HBV) infection), or to alcohol abuse (19%). Combined viral and alcoholic (ALD) cirrhosis represented 2.4% of indications, with 2% of HCV-ALD. Cirrhosis is followed by three major indications: primary liver tumors (17%, predominantly hepatocellular carcinoma – HCC, 15%), cholestatic liver diseases (10%), and acute hepatic failure (9.1%, 2% of which are virus-related, 2.4% drug related, 0.3% toxic nondrug related and 4.4% of unknown cause). The most common etiologies of the underlying cirrhosis in HCC patients were HCV (43%), ethanol abuse (27%), and HBV (16%). Cholestatic diseases included primary biliary cirrhosis (5%) and primary sclerosing cholangitis (5%). Biliary atresia (4%)




Figure 3 Evolution of indication according to three eras.

represented the major congenital biliary disease. Metabolic diseases represented 6% of all the indications with three major indications being familial amyloidotic polyneuropathy, Wilson disease, and alpha-1-antitrypsin deficiency (1% each). Budd-Chiari and benign liver tumors (mainly polycystic disease) represented only 1% of the indications for LT. Secondary liver tumors (mainly neuroendocrine) represented 0.5% of LT's.

Indications for Pediatric liver transplants

The proportions of the main indications for LT are differently distributed according to the age of recipients. While biliary atresia and metabolic diseases were the major indications in pediatric patients (≤18 years), cirrhosis with end stage liver disease, and cancer were the major indications in adults. An exponential increase in the proportion of cancer cases was noted with recipient age. Acute liver failure (ALF) mostly of unknown cause was frequent in young patients, with the highest incidence at 18–24 years.

Evolution of indications

The percentage of main indications has significantly changed with time (Fig. 3). Whereas cancers represented 12% of indications before 1997, their incidence has doubled in the last decade to represent currently more than 24%. Metabolic diseases and primary sclerosing cholangitis have slightly increased during the last decade. Conversely, while comparing the last decade with the previous one, we found that the proportion of cirrhosis alone, ALF and primary biliary cholangitis decreased. The decrease in cirrhosis is mainly because of the decrease in HCV cirrhosis, and the reduction in ALF cases is mainly because of the decline of ALF of unknown origin.

Survival according to the indication for LT

When all indications were considered, during the entire study period, patient survival rates were 83% at 1 year, 71% at 5 years, 61% at 10 years, 51% at 15 years, and




Figure 4 Patient survival versus period of liver transplantation, n = 119 125 (1968–2016).




Figure 5 Patient survival versus period of liver transplantation: (a) Cirrhosis, $n = 65\,502$ (1968–2016), (b) AHF, $n = 8782$ (1968–2016). (c) Cancer, $n = 19\,685$ (1968–2016).

41% at 20 years. After an improvement between 1985 and 2000, the survival of patients appears to be relatively steady since 2000 (Fig. 4).

The improvement in survival was seen in patients transplanted for all the three main indications; cirrhosis (Fig. 5a), fulminant hepatitis (Fig. 5c) but was particularly regular in LT for cancers (Fig. 5c). The 5-year patient survival rate was significantly better for cirrhosis (71%) than for primary liver tumors (64%, $P < 0.001$) and acute hepatic failure (65%, $P < 0.001$). HBV and HCV co-infection had a better 5-year survival (80%) compared with mono-infection with HCV (64%) or HBV (74%). The better 5-year survival rates obtained in metabolic diseases (79%), cholestatic disease (79%), and congenital biliary disease (85%), are partly explained by the high percentage of children in these groups. The survival rates in adults and children were, respectively, 76% and 85% for metabolic diseases, 79% and 86% for cholestatic disease, and 82% and 85% for congenital biliary disease. The details of survival rates at 1, 5 and 10, 15 and 20 years according to the primary indication are listed in Table 1.

Although the 5-year survival improved in the 15 recent years for all the indications, the most important gain in survival was observed in LT for primary liver tumors (67%), liver metastases (61%), and acute liver failure (69%).

Since the adoption of the transplantation Model for End-stage Liver Disease (MELD) score in the majority of European countries in 2006–2007, the proportion of patients with a high MELD score (>30) at transplant has almost doubled. However, the survival of these patients is less optimal, especially for those with a MELD score at transplant higher than 40 (Fig. 6).

Survival according to donor and recipient characteristics

Donor characteristics

The majority of donors were male (57%). Fifty-eight percent were younger than 50 years, whereas 23% were older than 60 years. A gradual increase in the percentage of livers coming from septuagenarian donors was




Figure 6 Patient survival versus MELD before LT: cirrhosis without HCC, $N = 29\,999$ (1988–2016).

Evolution of donor age

N = 137 174




Figure 7 Evolution of donor age, N = 137 174.

observed (1% in 1993, 10% in 2005 and 20% in 2015) in relation to the increasing gap between a growing waiting list and a relatively stable donor pool (Fig. 7). Graft survival when organs were procured from donors younger than 55 years was significantly better than that with organs from donors older than 65 years (67% vs. 60% at 5 years, $P < 0.0001$) (Fig. 8). However, attention should be paid to the donor to recipient matching to interpret these results, older donor livers being more frequently transplanted to older recipients.

Recipient age

In addition to the better 5-year survival of pediatric versus adult LT recipients (90% vs. 81%, $P < 0.0001$), an influence of age was noted for adult recipients. Survival rates were 75% for adults aged 18–45 years, 71% for 46–60 years, 65% for 60–70 years, and 60% for septuagenarians. However, average age of transplanted recipients has increased steadily during the last decade, and patients older than 60 years, who represented <5% in

the 1980s, currently represent more than 30% of transplant recipients (Fig. 9). Older grafts are more frequently transplanted to older recipients. Septuagenarian recipients received 43% grafts older than 60-years and only 12% of grafts younger than 30-years, explaining at least in part, the difference in survival between recipient age groups (Fig. 10). Importantly, LT offered a 10-year survival up to 40% in septuagenarians.

Blood group compatible and incompatible transplants

In elective conditions, 93% of LTs were isogroup, and 6.5% were compatible, whereas in emergency, 3% of LT were incompatible. In both elective and emergency conditions, isogroup LTs had a better 5-year survival compared with compatible or incompatible LTs (66% vs. 62% vs. 57%, $P < 0.0001$) and (56% vs. 53% vs. 28%, $P = 0.001$) respectively. However, the use of these incompatible grafts in emergency indications allows a 38% survival rate at 1 year in patients otherwise expected to have a fatal outcome.




Figure 8 Graft survival versus donor age, $n = 133\,571$ (1988–2016).

Survival according to surgical technique

Auxiliary grafts represented 0.5% of overall LTs with a similar graft survival as compared with nonauxiliary grafts in urgent (5-year survival rates: 57% vs. 56%), and elective (66% vs. 69%) indications. The shorter the ischemia time; the better was the graft survival. Five-year survival was 70% for ischemia time <6 h, 67% for 6–12 h, 63% for 12–15 h, and 58% for >15 h. The use of static graft preservation solutions evolved during three distinct periods: period 1 before 1990 with the main use of Collins solution; period 2 between 1990 and 2000 with the almost exclusive use of UW (University of Wisconsin); period 3 after 2000 with an increasing use of new solutions with different characteristics such as HTK, Celsior, IGL 1 or SCOT (Fig. 11). Overall graft survival at 5 years for the main solutions was 74% for Celsior and IGL 1, 72% for UW and 69% for HTK (Fig. 12). If only partial livers were considered, survival was 83% for IGL 1, 79% for Celsior, 77% for UW, and 71% for HTK.

Alternative procedures to LT using full size livers from donors after brain death (DBD) have been increasingly used in recent years. While representing $<10\%$ before

2000 they concerned more than 20% of overall LT procedures after 2000 and 75% in pediatrics. A differentiation between adult and pediatric patients is necessary; because alternative techniques are used differently in each population and the patient's outcome may differ.

Adult population

Before 1994, alternative procedures concerned mainly reduced and split livers. Domino grafts were introduced in 1994 and living donation in 1996. Donation after cardiac death (DCD) was introduced in 2001 and since then, has gradually increased to represent currently almost 40% of the alternative procedures in adults. Consequently, the proportion of split, living, reduced, and domino grafts has decreased. The latter two modalities are really associated with the more significant decrease (Fig. 13a). Ten-year graft survivals for each type of graft are summarized in Fig. 13b. Survival at 5 years was similar between DBD full size grafts, split liver, domino, and DCD (66% to 67%), but higher than that of reduced grafts and living donors (63% in both).



Evolution of recipient age

N = 146 302




Figure 9 Evolution of recipient age, N = 146 302.

Pediatric population

Before 1988, alternative procedures concerned mainly reduced livers. Split livers were introduced in 1988 and living donation in 1991 and since their introduction both have gradually increased to represent currently more than 90% of the alternative procedures in children (Fig. 14a). Ten-year graft survivals for each type of graft are summarized in Fig. 14b. Survival at 5 years was similar between DCD and living donors (80% and 78%, respectively), but higher than that of DBD full size grafts, split liver, and reduced grafts (74%, 71%, and 65% respectively). Domino transplant is rarely used in pediatric patients.

Mortality after LT

While 1 year patient survival was 81% between 1995 and 1999, it has dramatically improved to reach 86%

after 2010 (Fig. 4). The critical period for post-LT outcome is represented by the first year: 46% of deaths and 67% of re-LT occur within the first year after LT (Fig. 15). In 44% of cases, re-LT is indicated in the month after primary LT, and more than a half (59%) of patients who die, do so within the 6 months after LT.

Data represented in Fig. 16 correspond to the distribution of main causes of death according to the time of their incidence. Main causes of death in the 28 637 patients who died after primary LT or Re-LT were differently distributed. Whereas death from primary graft nonfunction or dysfunction, infections, and technical (biliary or vascular) complications were more frequent within the first 6 months post-LT, tumor or nontumor recurrence and tumor *de novo* were more frequent after the first month. Interestingly, the proportion of tumor and nontumor recurrences as a cause of death is decreasing during the last years.



Patient survival vs. recipient age : adults
N = 114 487 (1988–2016)



Global Log Rank P = <0.0001




Figure 10 Patient survival versus recipient age: adults N = 114 487 (1988–2016).

Re-transplantation

Five-year graft survival rates following a second and a third LTs were 48% and 42%, respectively, significantly lower than those for primary LT (66% – P < 0.0001) (Fig. 17).

Re-LT was indicated in 8482 cases mainly for primary nonfunction, technical complications (biliary or vascular), and rejection within the first month post-LT. Tumor or nontumor recurrences and *de novo* tumor were more frequent after the first month (Fig. 18). Late re-LT, more than 1 month after the first LT, has a significantly better graft survival than early re-LT performed within the month after the first LT (50% vs. 45% at 5 years, P < 0.0001) (Fig. 19). Re-LT which is mostly used in young patients (Fig. 3a) has declined during the last decade (Fig. 3b). Interestingly, tumor causes and nontumor recurrence are decreasing during the last years, whereas technical complications, primary graft nonfunction or dysfunction and infection are increasing.

Waiting time

When more than 90% of candidates waited <3 months in the 1980s, they represented 70% in the 1990s and slightly more than a half since 2000. This evolution is likely because of three main reasons: the increase in the number of candidates for transplantation following the advent of more and more effective immunosuppressive treatments, the scarcity of grafts and the use of the MELD which gives priority to the sickest candidates. The 5-year survival of patients who have spent <3 months on the waiting list, certainly because they were more severe, was 70%, 5% lower than that of all the other groups of waiting times in the list (P < 0.0001).

Discussion

The ELTR data provide a descriptive overview of the overall situation of LT in Europe. There is of course heterogeneity in the policies in the 29 contributing countries. This manuscript summarizes the results as



Evolution of preservation liquid used in liver transplantation in Europe

$N = 116\ 055$ overall population




Figure 11 Evolution of preservation liquid used in liver transplantation in Europe, $n = 116\ 055$ overall population.

a whole, and represents a kind of freeze-frame rather than a generalized statement for Europe. At the same time, the ELTR remains the unique entity capable of providing such statistics, capable of giving a global snapshot of the European experience, and helping to identify important trends that may guide further practice.

Liver transplantation has become the best, if not the only effective treatment for severe irreversible liver disease. More than 7000 LTs are performed annually in Europe, and the results look satisfactory at 5 years (71% survival) with still a room for improvement at long-term (61% at 10 years and 41% at 20 years). The demand far exceeds the availability of organs for transplantation. It is therefore essential to continue to promote organ donation in Europe in order to avoid mortality on the waiting list, and a “drastic” selection of candidates. By allowing the transplant of the sickest candidates first, the MELD score has dramatically decreased the risk of death on the waiting list. However, the post-LT survival of high MELD

score patients is less optimal, mostly for those with MELD score at transplant higher than 40. It also appears essential to continue to improve the perioperative management of LT at all levels, along with a better prevention of long-term complications. The data provided by the ELTR are a basis to target the timing, and fields to improve the results.


The main indication for LT is cirrhosis with end stage liver disease. However, its proportion is decreasing continuously as compared with HCC. Fulminant hepatitis of unknown cause is also declining. Such relative diminution of cirrhosis is mainly related to the accelerated decline in HCV indications as a result of effective direct-acting antiviral drugs [17]. Thus, hundreds of liver grafts every year are becoming available for indications other than HCV. Even though NASH related cirrhosis is still less frequent in Europe compared with the US, it is anticipated to become the leading indication for LT within the next decade.



Patient survival vs. MAIN preservation liquid
N = 100 005 Overall population (1988–2016)



Global Log Rank P = <0.0001



Details : Log rank P

proba		
UW	CU/HTK	<0.0001
UW	CE	0.0004
UW	IGL	0.014
CU/HTK	CE	<0.0001
CU/HTK	IGL	<0.0001
CE	IGL	0.85

Survival %	preserv_liq_c	1 year	3 years	5 years	8 years	10 years	12 years	14 years	16 years	18 years	20 years
UW: University Wisconsin		84%	77%	72%	66%	62%	57%	53%	49%	45%	41%
CU/HTK		82%	74%	69%	61%	55%	50%	46%	43%	38%	37%
CE: Celsior		86%	79%	74%	67%	61%	57%	53%	51%	51%	51%
IGL: IGL		87%	80%	74%	65%	61%					

Number of exposed patients	Total	1 year	3 years	5 years	8 years	10 years	12 years	14 years	16 years	18 years	20 years
UW: University Wisconsin	61 288	46 592	37 560	30 864	21 906	16 781	12 273	8669	5775	3493	1878
CU/HTK	21 027	12 826	7287	4613	1897	912	425	223	108	42	31
CE: Celsior	13 544	9339	5797	3718	1548	703	275	85	4	3	1
IGL: IGL	4146	2722	1587	853	261	63	0	0	0	0	0

Figure 12 Patient survival versus main preservation liquid, n = 100 005 overall population (1988–2016).

In terms of results, all the indications have shown an improvement of survival especially HCC, mainly because of a better selection of patients, and the increasing effectiveness of down-staging techniques [18]. The ELTR cohort of patients has also established that some rare malignant tumors like hepatic hemangiosarcoma should be considered absolute contraindications for LT [19], while others like hereditary hemorrhagic telangiectasia [8] or hepatic epithelioid hemangio-endothelioma represent a good indication even in the presence of limited extrahepatic disease [12,24].

The average age of transplanted recipients has increased steadily during the last decade and a third of patients transplanted nowadays are >60 years. Noteworthy, LT can offer a 10 additional year benefit to 40% of septuagenarians. Also, an increasing number of transplanted liver grafts are coming from older donors with in most cases, the application of the old-to-old rule concerning the donor to recipient matching.

Alternatives to the conventional DBD full size graft are increasingly used in Europe. Split liver and living


donation are increasingly used both in adult and pediatric LT, and DCD grafts are mostly used in adults with quite good survival results. Domino and reduced livers seem to be gradually disappearing. Optimization of donor management and organ preservation, offers the most realistic way to improve both the quality and pool of current organs. While only UW solution was used before 2000, an increasing number of new solutions are available today; the choice in preservation solution may have an independent impact on graft survival [25].

Also, while the introduction of cyclosporine and more recently Tacrolimus optimized immunosuppressive protocols, there is still room for improvement as recently shown by the use of prolonged release tacrolimus [26].

As a cause of graft loss, technical complications, primary graft nonfunction or dysfunction and infection are increasing, relatively. This could be related to the increasing use of marginal grafts coming from expanded donor criteria. Conversely, *de novo* tumor and nontumor recurrence as cause of graft loss or mortality are decreasing during the last years.




Evolution of Alternatives to the use of full size DBD liver grafts in Europe N = 12 276 Adults



Graft survival vs. type of graft : Adults N = 87 127 (2001–2016)



Global Log Rank $P = <0.0001$




Survival %	Type_of_liver_graft	1 year	2 years	3 years	4 years	5 years	6 years	7 years	8 years	9 years	10 years
Domino		82%	76%	71%	67%	66%	64%	59%	54%	49%	45%
Living donor		77%	72%	69%	66%	63%	62%	60%	58%	56%	54%
Full size DBD		80%	76%	72%	69%	67%	64%	61%	59%	56%	54%
Reduced		74%	72%	66%	65%	63%	63%	56%	54%	54%	54%
Split liver		75%	72%	70%	67%	66%	63%	61%	58%	55%	53%
Non heart beating		83%	77%	74%	70%	67%	65%	61%	57%	53%	47%

Number of exposed patients	Total	1 year	2 years	3 years	4 years	5 years	6 years	7 years	8 years	9 years	10 years
Domino	810	586	500	431	367	332	277	218	158	120	92
Living donor	4894	2450	1681	1325	1088	866	719	559	446	351	282
Full size DBD	76 415	51 605	42 566	35 463	30 034	25 490	21 379	17 596	14 170	11 141	8706
Reduced	171	99	82	66	56	44	39	31	28	24	19
Split liver	2878	1792	1521	1282	1089	960	813	656	502	378	279
Non heart beating	1959	1188	822	617	457	328	235	159	80	45	21

Figure 13 (a) Evolution of alternatives to the use of full size donors after brain death (DBD) liver grafts in Europe, $n = 12\,276$ adults. (b) Graft survival versus type of graft: Adults, $N = 87\,127$ (2001–2016).




Evolution of Alternatives to the use of full size DBD liver grafts in Europe N = 8666 Children



Graft survival vs. type of graft : Children N = 9440 (2001–2016)



Global Log Rank P = <0.0001



Survival %	Type_of_liver_graft	1 year	2 years	3 years	4 years	5 years	6 years	7 years	8 years	9 years	10 years
Domino		91%	91%	91%	91%	91%	91%	91%	91%	91%	91%
Living donor		83%	82%	80%	79%	78%	77%	75%	75%	75%	75%
Full size DBD		83%	80%	78%	75%	74%	72%	71%	70%	69%	68%
Reduced		73%	70%	68%	66%	65%	65%	64%	64%	63%	63%
Split liver		78%	75%	74%	72%	71%	70%	69%	68%	67%	66%
Non heart beating		88%	83%	80%	80%	80%	75%	75%	75%	75%	75%

Number of exposed patients	Total	1 year	2 years	3 years	4 years	5 years	6 years	7 years	8 years	9 years	10 years
Domino	17	9	3	3	3	3	2	2	2	1	1
Living donor	2710	1518	1178	942	783	640	527	438	311	240	185
Full size DBD	2808	1936	1591	1332	1125	966	836	702	570	468	375
Reduced	594	391	348	309	272	239	206	186	166	139	115
Split liver	3241	2100	1759	1484	1277	1101	954	797	625	469	367
Non heart beating	70	45	31	26	20	19	14	11	7	5	4

Figure 14 (a) Evolution of alternatives to the use of full size donors after brain death (DBD) liver grafts in Europe, N = 8666 children. (b) Graft survival versus type of graft: children, N = 9440 (2001–2016).



Mortality and retransplantation post LT in Europe (1988–2016)




Figure 15 Mortality and retransplantation post LT in Europe (1988–2016).



Mortality following first liver transplantation in Europe N = 28 637 (1988–December 2016)




Figure 16 Mortality following first liver transplantation in Europe, N = 28 637 (1988–December 2016).




Figure 17 Graft survival versus number of the LT, N = 141 924 (1988–2016).




Figure 18 Causes of retransplantation following first liver transplantation in Europe, N = 8482 (1988–December 2016).



Graft survival vs. early or late ReLT1 N = 147 205 (1988–2017)


Global Log Rank $P = <0.0001$ 

Figure 19 Graft survival versus early or late ReLT1, $N = 147\,205$ (1988–2017).

There are some limitations to our study. Data quality, reliability, and representativeness is an everyday concern for the ELTR since its creation in 1986. With this constantly in mind, the ELTR has implemented several procedures and adapted them all along the years to control the quality of data, from collection, to statistical analysis. However, biases may persist as for all observational studies; therefore, the interpretation of these descriptive data must be done with caution. Lost-to-follow-up (LTFU) patients are a real problem in the reported outcome. It is mainly related to the increasing number of transplanted patients who move to another place within a country or outside the country. More than 72% of ELTR data are shared with official OSOs who have setup a drastic tracking procedure to minimize the rate of LTFU. The remaining 28% who enter the data directly in our platform are regularly invited to consult the dynamically updated list of queries to solve all discrepancies and to report a recent patient follow-up.

By the prospective evaluation of almost all patients transplanted in Europe since the last fifty years, the ELTR provides valuable data concerning the evolution of LT, the dynamic changes in indications, in donor

and recipients profile, as well as in preservation, technical aspects and post-transplant management. These data can help refine the indications for transplant in rare diseases, and establish new guidelines, while targeting the real fields which need improvement in order to optimize the results of LT.

Authorship

RA, VK and VC: conception and design, acquisition of data, data analysis and interpretation of results, writing the first draft, critical revision, final approval. All the rest of co-authors: acquisition of data, critical revision, final approval.

Funding

The authors have declared no funding.

Conflicts of interest

The authors have declared no conflicts of interest.

Acknowledgements

The authors are indebted to all the 174 contributing centers that are listed at the following link <http://www.eitr.org/spip.php?page=centers-tous>.

The ELTR is supported by a grant from Astellas, Novartis France, Institut Georges Lopez, Bridge to Life and logistic support from the Paul Brousse Hospital (Assistance Publique – Hôpitaux de Paris). The Organ

Sharing Organizations: the French ABM (Sami Djabbour and Alain Jolly), the Eurotransplant Foundation (Marieke Van Meel and Erwin de Vries), the Spanish ONT (Gloria de la Rosa), the UK-Ireland NHSBT (Mike Chilton and Julia Micciche), the Dutch NTS (Cynthia Konijn) are acknowledged for the data cross-check and sharing with the ELTR.

REFERENCES

- International figures on organ donation and transplantation activities 2016. <http://www.transplant-observatory.org>
- Adam R, McMaster P, O'Grady JG, *et al.* Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. *Liver Transpl* 2003; **9**: 1231.
- Karam V, Gunson B, Roggen F, *et al.* Quality control of the European Liver Transplant Registry: results of audit visits to the contributing Centres. *Transplantation* 2003; **75**: 2167.
- Morris P, Monaco A. Quality control of transplant registries. *Transplantation* 2003; **75**: 2162.
- Hanto D. Reliability of voluntary and compulsory databases and registries in the United States. *Transplantation* 2003; **75**: 2162.
- Van Der Meulen J, Jacob M, Copley L. Assessing the quality of the data in a transplant registry: the European Liver Transplant Registry. *Transplantation* 2003; **75**: 2164.
- Mentha G, Giostra E, Majno PE, *et al.* Liver transplantation for Budd-Chiari syndrome: a European study on 248 patients from 51 centres. *J Hepatol* 2006; **44**: 520.
- Lerut J, Orlando G, Adam R, *et al.* Liver transplantation for hereditary hemorrhagic telangiectasia: report of the European liver transplant registry. *Ann Surg* 2006; **244**: 854.
- Mutimer DJ, Gunson B, Chen J, *et al.* Impact of donor age and year of transplantation on graft and patient survival following liver transplantation for hepatitis C virus. *Transplantation* 2006; **81**: 7.
- De Kerckhove L, De Meyer M, Verbaandert C, *et al.* The place of liver transplantation in Caroli's disease and syndrome. *Transpl Int* 2006; **19**: 381.
- Melzi ML, Kelly DA, Colombo C, *et al.* Liver transplant in cystic fibrosis: a poll among European centers. A study from the European Liver Transplant Registry. *Transpl Int* 2006; **19**: 726.
- Lerut JP, Orlando G, Adam R, *et al.* The place of liver transplantation in the treatment of hepatic epitheloid hemangioendothelioma: report of the European liver transplant registry. *Ann Surg* 2007; **246**: 949.
- Burra P, Senzolo M, Adam R, *et al.* Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). *Am J Transplant* 2010; **10**: 138.
- Schramm C, Bubenheim M, Adam R, *et al.* Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry. *Liver Transpl* 2010; **16**: 461.
- Wahlin S, Stål P, Adam R, *et al.* Liver transplantation for erythropoietic protoporphyria in Europe. *Liver Transpl* 2011; **17**: 1021.
- Mergental H, Adam R, Ericzon BG, *et al.* Liver transplantation for unresectable hepatocellular carcinoma in normal livers. *J Hepatol* 2012; **57**: 297.
- Belli LS, Perricone G, Adam R, *et al.* Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry. *J Hepatol* 2018; **69**: 810.
- Pommergaard HC, Rostved AA, Adam R, *et al.* Locoregional treatments before liver transplantation for hepatocellular carcinoma: a study from the European Liver Transplant Registry. *Transpl Int* 2018; **31**: 531.
- Orlando G, Adam A, Mirza D, *et al.* Hepatic hemangiosarcoma: an absolute contraindication to liver transplantation—the European Liver Transplant Registry experience. *Transplantation* 2013; **95**: 872.
- Le Treut YP, Grégoire E, Klemptner J, *et al.* Liver transplantation for neuroendocrine tumors in Europe—results and trends in patient selection: a 213-case European liver transplant registry study. *Ann Surg* 2013; **257**: 807.
- Chiche L, David A, Adam R, *et al.* Liver transplantation for adenomatosis: European experience. *Liver Transpl* 2016; **22**: 516.
- Mantel HT, Westerkamp AC, Adam R, *et al.* Strict selection alone of patients undergoing liver transplantation for hilar cholangiocarcinoma is associated with improved survival. *PLoS ONE* 2016; **11**: e0156127.
- Krawczyk M, Grąt M, Adam R, *et al.* Liver transplantation for hepatic trauma: a study from the European Liver Transplant Registry. *Transplantation* 2016; **100**: 2372.
- Lai Q, Feys E, Karam V, *et al.* Hepatic epitheloid hemangioendothelioma and adult liver transplantation: proposal for a prognostic score based on the analysis of the ELTR-ELITA Registry. *Transplantation* 2017; **101**: 555.
- Adam R, Delvart V, Karam V, *et al.* Compared efficacy of preservation solutions in liver transplantation: a long-term graft outcome study from the European Liver Transplant Registry. *Am J Transplant* 2015; **15**: 395.
- Adam R, Karam V, Delvart V, *et al.* Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. *Am J Transplant* 2015; **15**: 1267.
- Adam R, Cailliez V, Majno P, *et al.* Normalised intrinsic mortality risk in liver transplantation: European Liver Transplant Registry study. *Lancet* 2000; **356**: 621.
- Burroughs AK, Sabin CA, Rolles K, *et al.* 3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. *Lancet* 2006; **367**: 225.